Parallel Advisors’s Kronos Bio KRON Stock Holding History

Parallel Advisors’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$162	–	3465
2022 Q4	$162	Buy	+100	New	+$230	﹤0.01%	3217
2021 Q4	–	Sell	-211	Closed	-$4K	–	3194
2021 Q3	$4K	Buy	+211	New	+$4.53K	﹤0.01%	2464

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Parallel Advisors's KRON Position: Q1 2023 in Review

Parallel Advisors sold out of Kronos Bio (KRON) in Q1 2023, closing a stake of 100 shares — an estimated $162 sold.

Parallel Advisors first reported a position in KRON in Q3 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 87 funds tracked by Wall St. Rank hold KRON as of Q1 2023.

Parallel Advisors reported no remaining Kronos Bio position as of Q1 2023 after selling out during the quarter.
Parallel Advisors sold 100 Kronos Bio shares in Q1 2023, an estimated $162.
Parallel Advisors first reported a position in Kronos Bio in Q3 2021 and held it in 2 quarters.
Parallel Advisors's Kronos Bio position peaked at $4K in Q3 2021.
87 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.